CrossBridge Bio raises $300.0M (United States, Jun 2026)
$300.0M
$300 millionGenerated social card
Headline
Eli Lilly scoops up Houston biotech startup in $300 million deal - InnovationMap
About
CrossBridge Bio is a Houston-based biotech startup that develops antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2023, the company is notable for its innovative approach to combining targeted therapy with chemotherapy, aiming to kill cancer cells while preserving healthy tissue.
Article summary
Eli Lilly scoops up Houston biotech startup in $300 million deal InnovationMap
Investors · 6
4 hiddenRelated rounds
| Jul 13, 2026 | Ravee Optics | $6.0M | Seed | United States |
| Jul 13, 2026 | Luxonis | $14.0M | Series A | United States |
| Jul 13, 2026 | Guthrie AI | $4.0M | — | United States |
| Jul 13, 2026 | Together AI | $800.0M | Series C | United States |